East Windsor, NJ, United States of America

David S Weinstein

This inventor holds 41 USPTO granted patents and 11 published patent applications, plus 2 CIPO patents and 15 EPO patents, primarily in Immunology Modulators. Top assignees: Bristol-Myers Squibb Compnay, Vividion Therapeutics, Inc., Scripps Research Institute. Active years: 2005-2026.

USPTO Granted Patents = 41 (Patent Applications = 11)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 15 (Patent Applications = 19)

Average Co-Inventor Count = 4.0

ph-index = 8

Forward Citations = 165(Granted Patents)

Location History:

East Windsor, NJ (US) (2005 - 2019)
La Jolla, CA (US) (2019)
San Diego, CA (US) (2019 - 2023)

Company Filing History:

37 out of 3,733

Bristol-Myers Squibb Compnay

patents

4 out of 4

Vividion Therapeutics, Inc.

patents

3 out of 1,203

Scripps Research Institute

patents

where one patent can have more than one assignee

Years Active: 2005-2026

Loading Chart...

Areas of Expertise:

Interleukin Modulators

Glucocorticoid Receptor

Cereblon Modulators

Heterocyclic Compounds

Heteroaryl Compounds

Pharmaceutical Compositions

Inhibitors

Pyridine Compounds

Amide Compounds

15-Lipoxygenase

Imidazopyridazine

Tricyclic Compounds

41 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12528782 - Prodrugs in the modulation of interleukin (2026-01-20),

2. 12479831 - Substituted N(-methyl-D3)pyridazine-3-carboxamide or M-(methyl-D3)-nicotinamide compounds as IL-12, IL-23 and/or IFNα modulators (2025-11-25),

3. 12365667 - Sulfone pyridine alkyl amide-substituted heteroaryl compounds (2025-07-22),

4. 12187685 - Pharmaceutical compositions comprising WRN helicase inhibitors (2025-01-07),

5. 11787779 - Sulfone pyridine alkyl amide-substituted heteroaryl compounds (2023-10-17),

6. 11771689 - Cereblon modulators and uses thereof (2023-10-03),

7. 11597721 - Heterocyclic compounds comprising pyridine useful as modulators of IL-12, IL-23 and/or IFNα responses (2023-03-07),

8. 11299494 - Substituted imidazo[1,2-b]pyridazines as interleukin-23 and interferon-α modulators (2022-04-12),

9. 11021475 - Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses (2021-06-01),

10. 11021462 - Sulfone pyridine alkyl amide-substituted heteroaryl compounds (2021-06-01),

11. 10869860 - Cereblon modulators and uses thereof (2020-12-22),

12. 10781239 - In vivo engineered cereblon protein (2020-09-22),

13. 10781215 - Heterobicyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses (2020-09-22),

14. RE47929 - Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses (2020-04-06),

15. 10479793 - Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses (2019-11-19),

Title: David S. Weinstein: A Leader in Pharmaceutical Innovations

Introduction

David S. Weinstein, based in East Windsor, NJ, has made a significant impact in the field of pharmaceuticals with his innovative contributions. With a remarkable portfolio of 38 patents, he has demonstrated his expertise and commitment to developing therapeutic solutions, particularly for challenging diseases like cancer.

Latest Patents

Among his latest innovations, David has developed pharmaceutical compositions comprising WRN helicase inhibitors. These compounds are essential in treating proliferative diseases such as cancer. Specifically, they include compounds of Formula (I), which can be used in various pharmaceutically acceptable forms, offering potential new avenues for treatment.

Another notable patent involves sulfone pyridine alkyl amide-substituted heteroaryl compounds, which play a role in modulating immune responses by acting on Tyk-2. This advancement could lead to improved therapies targeting interleukin pathways, highlighting David's versatile expertise in the pharmaceutical domain.

Career Highlights

David's career is marked by his affiliation with prominent companies, including Bristol-Myers Squibb Company and Vividion Therapeutics, Inc. His work at these organizations has allowed him to advance his research and bring his innovative ideas to fruition, solidifying his reputation as a leading inventor in the pharmaceutical industry.

Collaborations

Throughout his career, David has worked alongside talented colleagues, including Ryan M. Moslin and Stephen T. Wrobleski. Their collaborations have fostered a creative environment that encourages groundbreaking research and developments in pharmaceutical compositions.

Conclusion

In conclusion, David S. Weinstein's contributions to the field of pharmaceuticals are significant and impactful. With a strong track record of patents and collaborative efforts, he continues to lead the way in developing innovative solutions for complex health challenges. His work not only demonstrates his expertise but also exemplifies the potential of innovative thinking in transforming medical treatment and patient care.